ZIVO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZIVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Zivo Bioscience's revenue for the three months ended in Dec. 2024 was $0.09 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $0.16 Mil. Zivo Bioscience's Revenue per Share for the three months ended in Dec. 2024 was $0.03. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.05.
During the past 12 months, the average Revenue per Share Growth Rate of Zivo Bioscience was 194.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Zivo Bioscience's highest 3-Year average Revenue per Share Growth Rate was 247.10% per year. The lowest was -50.20% per year. And the median was -13.70% per year.
The historical data trend for Zivo Bioscience's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zivo Bioscience Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Revenue | Get a 7-Day Free Trial |
![]() |
![]() |
0.02 | - | - | 0.03 | 0.16 |
Zivo Bioscience Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Revenue | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.01 | 0.04 | - | 0.03 | 0.09 |
For the Biotechnology subindustry, Zivo Bioscience's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Zivo Bioscience's Revenue distribution charts can be found below:
* The bar in red indicates where Zivo Bioscience's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zivo Bioscience (OTCPK:ZIVO) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Zivo Bioscience's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark E Strome | 10 percent owner | 100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401 |
John Bernard Payne | director | 9900 NE 114TH CIRCLE, VANCOUVER WA 98662 |
Alison A Cornell | director | 210 CARNEGIE CENTER, PRINCETON NJ 08540 |
Christopher D. Maggiore | officer: CHIEF FINANCIAL OFFICER | 4788 NOBLES POND DR. NW, CANTON OH 44718 |
Nola E Masterson | director | 768 WEST CALIFORNIA WAY, WOODSIDE CA 94062 |
Strome Mezzanine Fund, Lp | 10 percent owner | 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401 |
Keith Marchiando | officer: Chief Financial Officer | C/O ZIVO BIOSCIENCE, INC., 21 E. LONG LAKE ROAD, SUITE 100, BLOOMFIELD HILLS MI 48304 |
Strome Alpha Fund L P | 10 percent owner | 100 WILSHIRE BLVD SUITE 1750, SANTA MONICA CA 90401 |
Strome Investment Management Lp | 10 percent owner | 100 WILSHIRE BLVD, 15TH FLOOR, SANTA MONICA CA 90401 |
Strome Group, Inc. | 10 percent owner | 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401 |
Hep Investments Llc | 10 percent owner | 2804 ORCHARD LAKE RD, STE 205, KEEGO HARBOR MI 48320 |
Rondeau Robert O Jr | director | 70 WEST LONG LAKE RD, STE 119, TROY MI 48098 |
Thomas Kevin Cox | director | 470 MICHGAMME LANE, LAKE FOREST IL 60045 |
Andrew A Dahl | officer: President, CEO | 7 WEST SQUARE LAKE ROAD, STE 6165, BLOOMFIELD HILLS MI 48302 |
Brian W Young | other: See remarks below. | 1800 NW CORPORATE BLVD, BOCA RATON FL 33431 |
From GuruFocus
By Business Wire Business Wire • 05-30-2023
By Business Wire Business Wire • 08-10-2022
By Marketwired • 10-03-2023
By Marketwired Marketwired • 04-26-2021
By Business Wire • 06-30-2023
By Business Wire • 10-26-2023
By ACCESSWIRE ACCESSWIRE • 01-08-2021
By Marketwired Marketwired • 05-28-2021
By [email protected] [email protected] • 06-09-2020
By Marketwired Marketwired • 03-11-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.